Evaluating the Efficacy of Topical Insulin for the Restoration of Ocular Surface Interface in Dry Eye Disease.

Last updated: April 15, 2025
Sponsor: Khyber Teaching Hospital
Overall Status: Active - Recruiting

Phase

4

Condition

Stress

Diabetes (Pediatric)

Sjogren's Syndrome

Treatment

insulin human

Artificial tear

Clinical Study ID

NCT06939959
579/DME/KMC
  • Ages > 18
  • All Genders

Study Summary

This is a parallel randomized controlled trial for the treatment of dry eye disease. The main objective is to investigate the efficacy and safety of the use of insulin eye drops in the control of moderate-severe dry eye disease. Topical insulin drops will be compared to artificial tears in improving the ocular surface interface in patients with dry eye disease over 1 year period.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients having Schirmer's test values of less than 10mm after 5 minutes of theprocedure recording plus a non-invasive tear breakup time (TBUT) of less than 10seconds and the Ocular Surface Disease Index (OSDI) of more than 32 (diagnosed asdry eye disease as per the operational definition of this study).

  • any gender.

  • aged 18 years and above.

Exclusion

Exclusion Criteria:

  • Patients with active ocular infection, severe ocular surface disease other than Dryeye disease, and those who have undergone ocular surgery within the past 6 months.

  • Under 18 years old

Study Design

Total Participants: 126
Treatment Group(s): 2
Primary Treatment: insulin human
Phase: 4
Study Start date:
April 14, 2025
Estimated Completion Date:
April 20, 2026

Study Description

Patients fulfilling the selection criteria will be enrolled from eye OPD of KTH. A written informed consent will be taken after explaining the purpose of study. Data will be collected on a pre-designed structured proforma. Demographic data including age, gender, educational status, socioeconomic status will be noted. Each participant will undergo a complete history assessment and the OSDI score will be calculated after taking extensive history. Ophthalmologic examination, including visual acuity, refraction, slit-lamp examination, corneal staining, schirmer test and TBUT will be performed in each patient. Both eyes will be selected for each secondary outcome measure (TBUT & SCHIRMER TEST). However, only one OSDI score could only be obtained per patient for assessing primary outcome. All the previous medications used for dry eye will be stopped Participants' eyes will be randomized by blocked randomization in a 1:1 ratio to be treated with topical artificial tears (group I) and topical insulin 1U/ml (group II). The patients will be masked for the treatment, but not the principle investigator. Another investigator will prepare the topical insulin according to a written protocol. Participants will be given a white, unlabeled eye dropper containing the same volume of artificial tears or topical insulin for groups I and II respectively. Group I will receive artificial tears (control group) four times daily. Group II will receive topical insulin of 1u/ml four times daily. Follow-up assessments will be conducted at 4, 8 and 12 weeks for each participant to measure changes in TBUT, schirmer test, and OSDI score.

Connect with a study center

  • Khyber Teaching Hospital

    Peshawar, Khyber Pukhtunkhwa 25000
    Pakistan

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.